bioAffinity Technologies to Report Third Quarter 2022 Financial Results
November 08 2022 - 8:00AM
Business Wire
bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) today
announced that the Company will host a conference call and audio
webcast on Monday, Nov. 14, 2022, at 8 a.m. ET to discuss its
corporate and financial results for the third quarter of 2022.
The audio webcast will be accessible via the Investor Relations
section of the Company’s website, https://ir.bioaffinitytech.com/.
An archive of the webcast will be available for 90 days.
Additionally, interested participants and investors may access
the conference call by dialing one of the numbers below and
entering Conference ID BIAFQ322:
- 800-579-2543 (U.S.)
- 203-518-9856 (International)
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) addresses
the need for noninvasive diagnosis of early-stage cancer and
diseases of the lung, and targeted cancer treatment. The Company’s
first product, CyPath® Lung, is a non-invasive test that has shown
high sensitivity and specificity for the detection of early-stage
lung cancer. Precision Pathology Services licensed and developed
CyPath® Lung as a Laboratory Developed Test (LDT) and has begun
test marketing in Southeast Texas. OncoSelect® Therapeutics, LLC, a
subsidiary of bioAffinity Technologies, is advancing its
discoveries shown in vitro to kill cancer cells without harm to
normal cells. Research and optimization of the Company’s platform
technologies are conducted in its laboratories at The University of
Texas at San Antonio.
Forward-Looking Statements
This press release contains forward-looking statements,
including statements regarding the anticipated use of proceeds from
the Company’s offering of common shares. Forward-looking statements
can be identified by words such as “believes,” “expects,”
“estimates,” “intends,” “may,” “plans,” “will” and similar
expressions, or the negative of these words. Such forward-looking
statements are based on facts and conditions as they exist at the
time such statements are made and predictions as to future facts
and conditions. Readers of this press release are cautioned not to
place undue reliance on any forward-looking statements. The Company
does not undertake any obligation to update any forward-looking
statement relating to matters discussed in this press release,
except as may be required by applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221108005478/en/
Company Contact: Maria Zannes, President & Chief
Executive Officer mz@bioaffinitytech.com
Investor Relations Contact: Tiberend Strategic Advisors,
Inc. Jonathan Nugent jnugent@tiberend.com or David Irish
dirish@tiberend.com
bioAffinity Technologies (NASDAQ:BIAF)
Historical Stock Chart
From Mar 2024 to Apr 2024
bioAffinity Technologies (NASDAQ:BIAF)
Historical Stock Chart
From Apr 2023 to Apr 2024